PRESS RELEASE published on 08/15/2025 at 15:21, 7 months 7 days ago enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech enVVeno Medical Corporation to present at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 21, 2025, with CEO Robert Berman discussing innovative treatment solutions for deep venous disease Webinar EnVVeno Medical Corporation Bioprosthetic Solutions Deep Venous Disease Webull Financial
BRIEF published on 08/06/2025 at 14:35, 7 months 16 days ago VenoValve d'enVVeno Medical : une solution rentable pour les IVC sévères EnVVeno Medical Insuffisance Veineuse Chronique Approbation De La FDA Économies Sur Les Coûts Des Soins De Santé Valve VenoValve
BRIEF published on 08/06/2025 at 14:35, 7 months 16 days ago EnVVeno Medical's VenoValve: A Cost-Effective Solution for Severe CVI FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Healthcare Cost Savings
PRESS RELEASE published on 08/06/2025 at 14:30, 7 months 16 days ago Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency Preliminary findings show VenoValve as cost-effective & clinically beneficial for severe CVI. Webcast discussing results. Potential $5.9B annual healthcare savings. Study shows cost savings and clinical benefits Webcast VenoValve Healthcare Savings CVI Cost-Effectiveness
BRIEF published on 08/04/2025 at 15:10, 7 months 18 days ago EnVVeno Medical Explores Potential Impact of Trump's CVI Diagnosis on Treatment Options FDA Approval VenoValve CVI Diagnosis Trump Impact Healthcare Cost
BRIEF published on 08/04/2025 at 15:10, 7 months 18 days ago EnVVeno Medical étudie l'impact potentiel du diagnostic d'IVC de Trump sur les options de traitement. Approbation De La FDA Valve VenoValve Diagnostic De L'IVC L'impact De Trump Coût Des Soins De Santé
PRESS RELEASE published on 08/04/2025 at 15:05, 7 months 18 days ago enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company enVVeno Medical is developing the VenoValve as a potential treatment for Chronic Venous Insufficiency. FDA decision expected in 2H'2025 EnVVeno Medical VenoValve Chronic Venous Insufficiency FDA Decision Deep Venous Disease
BRIEF published on 08/01/2025 at 14:05, 7 months 21 days ago EnVVeno Medical Q2 2025 Financial Report and Corporate Update EnVVeno Medical VenoValve Q2 2025 Results EnVVe Progress FDA Decision
BRIEF published on 08/01/2025 at 14:05, 7 months 21 days ago Rapport financier et mise à jour de l'entreprise d'enVVeno Medical pour le deuxième trimestre 2025 EnVVeno Medical Valve VenoValve Résultats Du Deuxième Trimestre 2025 Progrès EnVVe Décision De La FDA
PRESS RELEASE published on 08/01/2025 at 14:00, 7 months 21 days ago enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update enVVeno Medical reports $3.8M cash burn & financial results for Q2 2025. Operations funded through Q3'2026 with sufficient cash. FDA decisions & clinical program progress on track Financial Results EnVVeno Medical Cash Burn FDA Decisions Clinical Program Progress
Published on 03/23/2026 at 11:30, 28 minutes ago Trans Canada Gold Provides Update on Non-Brokered Private Placement and Flow-through Private Placement for Drilling at the Harrison Lake District Scale Gold Property Acquisition
Published on 03/23/2026 at 08:00, 3 hours 58 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 9 hours 58 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 11:44, 13 minutes ago Viromed Medical AG receives funding approval from the Federal Ministry of Research, Technology and Space for the development of cold plasma technology
Published on 03/23/2026 at 11:30, 28 minutes ago EQS Group lance un module de gestion des risques pour faciliter la surveillance continue des risques liées aux données et à l’IA
Published on 03/23/2026 at 11:06, 51 minutes ago Aroundtown SA: Release of a capital market information
Published on 03/23/2026 at 11:05, 52 minutes ago ASUS Unveils Complete Portfolio Support for Intel® Core™ 200S Series
Published on 03/23/2026 at 11:05, 53 minutes ago BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology
Published on 03/23/2026 at 08:10, 3 hours 48 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 16 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 16 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 17 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 17 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA